about
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several ne...
Read More
257.12
2.12
(0.83%)
4.3M
XNYS Volume
XNYS 11 Sep, 2026 5:30 PM (EDT)
Board Meeting
The next board meeting for AbbVie is on 15 Sep 2026 for the purpose of the Morgan Stanley 24th Annual Global Healthcare Conference
See details
Not Eligible
Expensive Valuation
Technically Moderately Bullish
AbbVie Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..